AFYX Therapeutics
Private biopharmaceutical company providing targeted drug delivery for mucosal diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
$13.0m | Convertible | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (83 %) | (70 %) | 86 % | (64 %) | (8 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (25471 %) | (16884 %) | (33828 %) | (27576 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3816 %) | (22534 %) | (15520 %) | (36596 %) | (28234 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
AFYX Therapeutics is a pioneering healthcare startup specializing in the development of innovative mucoadhesive patches for the treatment of mucosal diseases. The company focuses on creating topical patches that adhere to mucosal surfaces, such as the oral cavity and vulvar area, to deliver medication directly to the affected site. This targeted approach aims to improve treatment efficacy while minimizing side effects.
AFYX Therapeutics primarily serves patients suffering from conditions like Vulvar Lichen Sclerosus and oral mucosal diseases. These conditions often require localized treatment, which AFYX's patches are designed to provide. The company operates in the biopharmaceutical market, specifically within the niche of mucosal drug delivery systems.
The business model of AFYX Therapeutics revolves around research and development (R&D) of these specialized patches, followed by clinical trials to ensure their safety and effectiveness. Once the products are proven effective, the company seeks regulatory approval to bring them to market. AFYX makes money by securing funding through convertible loans and investments, as well as through potential future sales of their approved products.
AFYX Therapeutics has already made significant strides, including closing a $13 million convertible loan financing and submitting Investigational New Drug (IND) and Clinical Trial Application (CTA) for Phase 2B studies. The company collaborates with renowned experts and institutions in dermatology and oral health to validate their products.
In summary, AFYX Therapeutics is dedicated to improving the lives of patients with mucosal diseases through innovative, targeted drug delivery systems. Their focus on R&D, clinical validation, and strategic partnerships positions them well in the biopharmaceutical market.
Keywords: mucoadhesive patches, mucosal diseases, biopharmaceutical, drug delivery, Vulvar Lichen Sclerosus, oral mucosa, clinical trials, R&D, healthcare, targeted treatment.